NDAORALTABLETPriority Review
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
7/8 — Comprehensive
Priority Review
JOURNAVX (suzetrigine) by Vertex Pharmaceuticals is sodium channel antagonists [moa]. Approved for sodium channel blocker [epc]. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JOURNAVX (suzetrigine) is an oral sodium channel antagonist approved January 30, 2025, for diabetic peripheral neuropathic pain, acute pain, and postoperative pain. It represents a non-opioid, mechanism-based alternative to traditional analgesics by blocking sodium channels to reduce pain signal transmission.
Growth14.6 years to LOE
As a newly approved product in growth phase with 14.6 years of patent protection, JOURNAVX represents a multi-year commercial ramp opportunity attracting field sales, regional leadership, and business development roles at Vertex.
Mechanism of Action
Sodium Channel Antagonists
Pharmacologic Class:
Sodium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
Suzetrigine for Non-Mastectomy Breast Surgery
Started Apr 2026
120 enrolled
Pain, Acute PostoperativeBreast Disease
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
Started Feb 2026
12 enrolled
Pain
Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports
Started Feb 2026
140 enrolled
Postoperative Pain Management
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Started Nov 2025
734 enrolled
Diabetic Peripheral Neuropathic Pain
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
Started Mar 2025
47 enrolled
Acute Pain
Worked on JOURNAVX at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.